Skip to content

[C-11]NOP-1A and Alcohol Use Disorder

Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Alcoholism

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03448016
Enrollment
54
Registered
2018-02-27
Start date
2016-05-27
Completion date
2021-03-30
Last updated
2022-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Brief summary

The goal of this study is to compare \[C-11\]NOP-1A binding in recently abstinent alcohol use disorders and controls

Detailed description

This will allow for understanding brain stress and antistress mechanisms that underlie abuse of alcohol in humans

Interventions

RADIATION[C-11]

Radiolabel

DRUGNOP-1A

Tracer

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Rajesh Narendran
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

\[C-11\]NOP-1A

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

\[A\] Alcohol use disorders (AUD) Inclusion Criteria: 1. Males or Females 2. Fulfill DSM5 diagnosis for alcohol use disorder 3. Medically Healthy

Exclusion criteria

1. Pregnancy or lactation 2. Comorbid severe/major medical, psychiatric (such as bipolar and psychotic disorders, etc.,) and current comorbid drug use disorders (other than tobacco use and recreational marijuana use) 3. Metal implants or paramagnetic objects contained within the body which may interfere with MRI scans 4. Currently employed as a radiation worker, or participation in radiation drug research procedures within the previous year 5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain \[B\]Healthy controls Inclusion Criteria: 1. Males or females 2. Absence of present or past psychiatric conditions (including alcohol or drug use disorders) 3. Medically Healthy

Design outcomes

Primary

MeasureTime frameDescription
[C-11]NOP-1A VTBaselineVT-Volume of distribution expressed relative to total plasma

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026